Document Detail

Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
MedLine Citation:
PMID:  21724396     Owner:  NLM     Status:  MEDLINE    
To identify serum biomarkers that allow monitoring of disease progression and treatment effects in Duchenne muscular dystrophy (DMD) patients, levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase-1 (TIMP-1) and osteopontin (OPN) were determined in 63 DMD patients on corticosteroid therapy. These proteins were selected for their role in the pathogenesis of muscular dystrophy. Levels of MMP-9 and TIMP-1 were significantly higher in sera of DMD patients compared to healthy controls, whereas the OPN levels showed no significant difference. MMP-9 levels were also observed to be significantly higher in older, nonambulant patients, compared to ambulant patients. Longitudinal data from a smaller cohort of DMD patients followed up for over 4years showed that MMP-9, but not TIMP-1 increased significantly with age. Hence, MMP-9 is a potential DMD biomarker for disease progression. Future studies have to confirm whether serum MMP-9 levels can be used to monitor therapeutic response.
V D Nadarajah; M van Putten; A Chaouch; P Garrood; V Straub; H Lochmüller; H B Ginjaar; A M Aartsma-Rus; G J B van Ommen; J T den Dunnen; P A C 't Hoen
Related Documents :
22703766 - Lack of association of the cd14/c -159t polymorphism with susceptibility and progressio...
22242146 - Disrupted functional brain connectivity in partial epilepsy: a resting-state fmri study.
18332896 - Assessment, diagnosis and treatment of a patient with hirsutism.
21655076 - Atypical supernumerary phantom limb and phantom limb pain in two patients with pontine ...
2680776 - Evaluation of the elderly hypertensive.
23778766 - Scoliometer measurements of patients with idiopathic scoliosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-07-02
Journal Detail:
Title:  Neuromuscular disorders : NMD     Volume:  21     ISSN:  1873-2364     ISO Abbreviation:  Neuromuscul. Disord.     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-08-02     Completed Date:  2012-01-19     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  9111470     Medline TA:  Neuromuscul Disord     Country:  England    
Other Details:
Languages:  eng     Pagination:  569-78     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier B.V. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Biological Markers / blood
Case-Control Studies
Child, Preschool
Disease Models, Animal
Disease Progression*
Longitudinal Studies
Matrix Metalloproteinase 9 / blood*
Mice, Inbred C57BL
Mice, Inbred mdx
Muscular Dystrophy, Duchenne / blood*,  drug therapy,  physiopathology*
Osteopontin / blood
Tissue Inhibitor of Metalloproteinase-1 / blood
Treatment Outcome
Young Adult
Grant Support
G0601943//Medical Research Council
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Biological Markers; 0/Tissue Inhibitor of Metalloproteinase-1; 106441-73-0/Osteopontin; EC Metalloproteinase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and ...
Next Document:  Nemaline myopathy caused by mutations in the nebulin gene may present as a distal myopathy.